Every woman, no matter her age, has her own reasons for wanting to use family planning. But not every woman has access to the contraception she needs.
In Uganda, nearly one-quarter of women who want to plan their pregnancies don’t have access to a form of contraception that meets the reality of their lives. Now a new injectable contraceptive called Sayana® Press is increasing access and choice for women in Uganda, Senegal, Burkina Faso, Niger, and beyond. It’s being introduced in these countries as part of a country-led initiative coordinated by PATH and supported by the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation (CIFF).
Sayana Press combines a low-dose formulation of the injectable contraceptive Depo-Provera® with the Uniject™ injection system, which was developed by PATH. The small, prefilled syringe is so easy to transport and use that it can be administered in remote locations by community health workers—or even by women themselves in their own homes.
Meet a few of the women who chose to tell their stories about why they use Sayana Press, and discover how finding the right contraceptive is changing their lives.
Sayana Press and Depo-Provera are registered trademarks of Pfizer Inc. Uniject is a trademark of BD.